Searchable abstracts of presentations at key conferences in endocrinology

ea0016oc4.4 | Bone and adrenal | ECE2008

Comparison of different test systems for the screening of inhibitors of CYP11B enzymes

Stuermer Andrea , Hahner Stafanie , Lang Katharina , Linss Heidi , Zink Martina , Schirbel Andreas , Allolio Bruno

Subject: Inhibitors of CYP11B enzymes, particularly of aldosterone synthase, are currently under development as adrenostatic agents in heart failure or hyperaldosteronism, and for use in adrenal imaging. As CYP11B1 and CYP11B2 show high homology, analysis of specific binding to the respective human enzymes is of key importance.Methods: Y1 cell lines stably expressing hsCYP11B1 or hsCYP11B2 were established. Primary cultures of porcine and human adrenocor...

ea0016p308 | Endocrine tumours | ECE2008

ERCC1 expression in adrenocortical carcinoma: relationship with baseline characteristics and response to platinum-based chemotherapy

Ronchi Cristina L , Sbiera Silviu , Adams Patrick , Kraus Luthgard , Linss Heidi , Wortmann Sebastian , Willenberg Holger , Allolio Bruno , Fassnacth Martin

Adrenocortical carcinoma (ACC) is a malignant tumor with poor prognosis and no established therapy in advanced stage. Cisplatin is the most frequently used cytotoxic drug, but even combined with doxorubicin and etoposid, the response rate is <50%. Recently, it has been demonstrated that the excision repair cross complementing group 1 (ERCC1) plays a relevant role in the DNA repairing process, particularly in the correction of platinum-induced DNA adducts. Accordingly, ERCC...